SCHEMBL6006650

SCHEMBL6006650

CCC(NC=O)c1ccc2ccccc2c1

nearest known ligand 0.43

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
UGT2B7 P16662 1/20 0.43
CYP2D6 P10635 7/20 0.42
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
CYP1A2 P05177 1/20 0.42
TSHR P16473 1/20 0.42
HIF1A Q16665 1/20 0.42
ATM Q13315 1/20 0.41
UTS2R Q9UKP6 4/20 0.41
SLC6A2 P23975 9/20 0.40
SLC6A4 P31645 9/20 0.40
SLC6A3 Q01959 9/20 0.40
KCNH2 Q12809 8/20 0.40
CYP3A4 P08684 6/20 0.40
MMP9 P14780 1/20 0.40
TPH1 P17752 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11787820 0.80 UGT2B7 (0.48) UGT2B7CYP2D6MEN1KMT2ACYP1A2
SCHEMBL13317650 0.79 MEN1 (0.47) MEN1KMT2ATSHR
SCHEMBL5223140 0.79 MEN1 (0.47) MEN1KMT2ATSHR
SCHEMBL6815513 0.78 MMP9 (0.54) UGT2B7CYP2D6MEN1KMT2ACYP1A2
SCHEMBL22342859 0.78 CYP2D6 (0.49) UGT2B7CYP2D6MEN1KMT2ACYP1A2
SCHEMBL6006645 0.77 UGT2B7 (0.43) UGT2B7CYP2D6MEN1KMT2ACYP1A2
SCHEMBL7733853 0.76 UTS2R (0.49) UGT2B7UTS2RMMP9TPH1
SCHEMBL14373867 0.75 ALDH1A1 (0.42) CYP2D6SLC6A2SLC6A4SLC6A3KCNH2
SCHEMBL7678705 0.75 UGT2B7 (0.47) UGT2B7CYP2D6MEN1KMT2ACYP1A2
SCHEMBL20318959 0.74 MAPK1 (0.40) MEN1KMT2ATSHRSLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1207161-B1 NOVEL ISOINDOLE DERIVATIVES BANYU PHARMA CO LTD (JP) 2006-01-18 EP disclosed
US-6777410-B2 SUCH AS 9-(2-METHOXYPHENYL)-3-(1-METHYLETHYL)-(1,3)OXAZOLO-(2,3)ISOINDOLE-2,5(3H,9H)-DIONE; DIABETES AND COMPLICATIONS; OBESITY BANYU PHARMACEUTICAL CO., LTD. (JP) 2004-08-17 US disclosed
US-20040053923-A1 Novel isoindole derivatives BANYU PHARMACEUTICAL CO., LTD. 2004-03-18 US disclosed
US-6608098-B1 Diabetes or obesity, 2-(4-(3-isopropyl-2,5-dioxo-2,3-dihydro-1H-pyrrolo(2,1-a) isoindol-9(5H)-yl)phenoxy)-N-propylacetamide BANYU PHARMACEUTICAL CO., LTD. (JP) 2003-08-19 US disclosed
EP-1207161-A1 NOVEL ISOINDOLE DERIVATIVES BANYU PHARMACEUTICAL CO., LTD. (JP) 2002-05-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040053923-A1 Novel isoindole derivatives GPR119, SLC5A2, SLC5A1 UGT2B7 707/4885CYP2D6 556/4885MEN1 4688/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.